Pharmacogenetics of HMG-CoA Reductase Inhibitors: Optimizing the Prevention of Coronary Heart Disease
作者： M. Hu , V. Mak , T. Chu , M. Waye , B. Tomlinson
DOI: 10.2174/187569209787582349
关键词:
摘要: The statins are the most important group of drugs for lipid-lowering therapy in prevention coronary heart disease. Greater reductions LDL-cholesterol appear to be associated with greater benefits but clinical efficacy and safety statin treatment varies considerably from person because a combination phenotypic genotypic factors. Pharmacogenetic studies have investigated relationship between common genetic variants lipid responses adverse events, some candidate genes related pharmacodynamics pharmacokinetics different been identified. Some these show frequency ethnic groups. This field pharmacogenetic research is receiving considerable attention many new findings reported recently. pharmacogenomic likely provide bet- ter understanding effects help prediction appropriate drug dosage each individual whether addition or substitution other modifying may necessary achieve safe effective
eurekaselect.com参考文章(227)
Bacchi S, Palumbo P, Sponta Am, Palumbo G, Primavera Lg, [Grapefruit juice: potential drug interaction]. Clinica Terapeutica. ,vol. 156, pp. 97- 103 ,(2005)
Ann K. Daly, Barry P. King, Julian B. S. Leathart, Genotyping for Cytochrome P450 Polymorphisms Cytochrome P450 Protocols. ,vol. 320, pp. 193- 208 ,(2006) , 10.1385/1-59259-998-2:193
Paul M Ridker, None, C-Reactive Protein and the Prediction of Cardiovascular Events Among Those at Intermediate Risk: Moving an Inflammatory Hypothesis Toward Consensus Journal of the American College of Cardiology. ,vol. 49, pp. 2129- 2138 ,(2007) , 10.1016/J.JACC.2007.02.052
Olga A. Iakoubova, Carmen H. Tong, Charles M. Rowland, Todd G. Kirchgessner, Bradford A. Young, Andre R. Arellano, Dov Shiffman, Marc S. Sabatine, Hannia Campos, Christopher J. Packard, Marc A. Pfeffer, Thomas J. White, Eugene Braunwald, James Shepherd, James J. Devlin, Frank M. Sacks, Association of the Trp719Arg Polymorphism in Kinesin-Like Protein 6 With Myocardial Infarction and Coronary Heart Disease in 2 Prospective Trials: The CARE and WOSCOPS Trials Journal of the American College of Cardiology. ,vol. 51, pp. 435- 443 ,(2008) , 10.1016/J.JACC.2007.05.057
Olga A. Iakoubova, Marc S. Sabatine, Charles M. Rowland, Carmen H. Tong, Joseph J. Catanese, Koustubh Ranade, Katy L. Simonsen, Todd G. Kirchgessner, Christopher P. Cannon, James J. Devlin, Eugene Braunwald, Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. Journal of the American College of Cardiology. ,vol. 51, pp. 449- 455 ,(2008) , 10.1016/J.JACC.2007.10.017
Roger G. Deeley, Ken-ichi Ito, Susan P.C. Cole, Monika Z. Vasa, Chris Westlake, Curtis J. Oleschuk, Mutation of Trp1254 in the Multispecific Organic Anion Transporter, Multidrug Resistance Protein 2 (MRP2) (ABCC2), Alters Substrate Specificity and Results in Loss of Methotrexate Transport Activity Journal of Biological Chemistry. ,vol. 276, pp. 38108- 38114 ,(2001) , 10.1074/JBC.M105160200
Rowland Yeo, Yeo, Wallis, Ramsay, Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients British Journal of Clinical Pharmacology. ,vol. 48, pp. 610- 615 ,(1999) , 10.1046/J.1365-2125.1999.00066.X
Thomayant Prueksaritanont, Bennett Ma, Nathan Yu, The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6 British Journal of Clinical Pharmacology. ,vol. 56, pp. 120- 124 ,(2003) , 10.1046/J.1365-2125.2003.01833.X
Curt D Furberg, Bertram Pitt, Withdrawal of cerivastatin from the world market Trials. ,vol. 2, pp. 205- 207 ,(2001) , 10.1186/CVM-2-5-205
K-W Park, J-H Choi, H-K Kim, S Oh, I-H Chae, H-S Kim, B-H Oh, M-M Lee, Y-B Park, Y-S Choi, The association of cholesteryl ester transfer protein polymorphism with high‐density lipoprotein cholesterol and coronary artery disease in Koreans Clinical Genetics. ,vol. 63, pp. 31- 38 ,(2003) , 10.1034/J.1399-0004.2003.630105.X